Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines

Journal of Neuro-Oncology, 05/08/2012

The data suggest the effectiveness of temozolomide (TMZ) in O6–methyl–guanidine–methyl–transferase (MGMT)–negative cancer stem cell (CSC) lines and support the concept of TMZ rechallenge. The 7 days on/7 days off scheme consistently showed the best activity of all schedules in TMZ–resistant CSC lines.

Print Article Summary Cat 2 CME Report